Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €57.00 EUR
Change Today +2.52 / 4.63%
Volume 28.9K
As of 11:35 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

financiere de tubize (TUB) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/4/14 - €61.00
52 Week Low
10/16/14 - €48.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FINANCIERE DE TUBIZE (TUB)

Related News

No related news articles were found.

financiere de tubize (TUB) Related Businessweek News

No Related Businessweek News Found

financiere de tubize (TUB) Details

Financière de Tubize SA/NV, through its interest in UCB SA/NV, operates as a biopharmaceutical company worldwide. The company is involved in the discovery and development of medicines and solutions in the therapeutic areas of central nervous system and immunology system. Its central nervous system products comprise Keppra that is used to treat partial onset seizures in adults, adolescents, children, and infants; Neupro for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, as well as idiopathic restless legs syndrome in adults; Metadate CD to treat attention deficit hyperactivity disorder; Nootropil for the treatment of vertigo and events associated with ageing; Xyrem, a sodium oxybate drug for narcolepsy with cataplexy in adult patients; and Vimpat, which is used as adjunctive therapy for the treatment of partial-onset seizures. The company’s immunology system products include Cimzia for the treatment of ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, and rheumatoid arthritis; Xyzal for treating allergic rhinitis, including persistent allergic rhinitis and chronic idiopathic urticaria; Zyrtec, an antihistamine for the symptomatic treatment of seasonal allergic rhinitis, perennial rhinitis, and chronic idiopathic urticaria; Tussionex for relief of cough and upper respiratory symptoms; and Lortab for the relief of severe pain. Financière de Tubize SA/NV is based in Brussels, Belgium.

financiere de tubize (TUB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

financiere de tubize (TUB) Key Developments

Financière de Tubize S.A. Reports Non-Consolidated and Consolidated Earnings Results for the First Half Ended June 30, 2015

Financiere de Tubize SA reported non-consolidated and consolidated earnings results for the first half ended June 30, 2015. On non-consolidated basis, profit was EUR 65.5 million. On consolidated basis, profit was EUR 89.6 million.

Financière de Tubize S.A. to Report First Half, 2015 Results on Jul 31, 2015

Financière de Tubize S.A. announced that they will report first half, 2015 results on Jul 31, 2015

Financiere de Tubize Proposes Gross Dividend for the Year 2014, Payable as from May 8, 2015; Reports Consolidated and Non Consolidated Earnings Results for the Year 2014

Financiere de Tubize proposed gross dividend of EUR 0.48 per share for the year 2014. The dividend will be payable as from May 8, 2015 with record date of May 7, 2015 and ex-date of May 6, 2015. The dividend will be approved in general shareholders meeting on April 22, 2015. The company reported consolidated and non consolidated earnings results for the year 2014. For the year, on consolidated basis, the company reported profit of EUR 59.7 million. For the year, on non-consolidated basis, the company reported profit of EUR 60.8 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TUB:BB €57.00 EUR +2.52

TUB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TUB.
View Industry Companies

Industry Analysis


Industry Average

Valuation TUB Industry Range
Price/Earnings 37.4x
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow 37.4x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FINANCIERE DE TUBIZE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at